Completed PHASE4 INTERVENTIONAL 1-arm NCT01126268

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

Sponsor: GlaxoSmithKline

Conditions Folliculitis Impetigo Minor Soft Tissue Infections Secondarily Infected Eczema

Updated 6 times since 2017 Last updated: Jan 20, 2016 Started: Apr 30, 2010 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01126268, this PHASE4 trial focuses on Folliculitis and Impetigo and remains completed. Sponsored by GlaxoSmithKline, it has been updated 6 times since 2010, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
The University of Texas Health Science Center, Houston

Data source: The University of Texas Health Science Center, Houston

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States